Added to YB: 2025-01-31
Pitch date: 2025-01-31
SKYE [bullish]
Skye Bioscience, Inc.
-67.37%
current return
Author Info
Investing Whisperer shares independent research on micro- and small-caps in Canada and the US. Sign up for the newsletter.
Company Info
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Market Cap
$45.2M
Pitch Price
$3.34
Price Target
37.50 (+3340%)
Dividend
N/A
EV/EBITDA
-0.19
P/E
-1.13
EV/Sales
N/A
Sector
Biotechnology
Category
growth
SKYE: A $88M Market Cap Biotech with a Potential 10-Bagger Catalyst in 2025
SKYE: CB1 inhibitor for weight loss, 16% in mice. Phase 2 human data Jun/Jul '25. $76.5M cash vs $88M cap. Less GI/psych issues vs GLP-1s. No muscle loss. Potential standalone/complement to GLP-1. Baker Bros & 5AM invested. 10x potential on positive data.
Read full article (1 min)